Three groups were selected. Group 1 who was vaccinated (Vaccination group), group 2, patients who recovered from Corona (Corona group) and group 3 who had neither Corona nor vaccination.After analysing the results, Dr. Verma stated that in the vaccination group after the first dose of vaccine, 80% developed antibodies and in 42% of this group the antibody status was maximum. In the Corona group, all had the highest level of antibodies while in group 3, the level was not detectable.
One month after the second dose, the level of antibodies was found in 85% and those who had not developed antibodies after the first dose, further 50% developed significant antibodies. In a nutshell, the study documents the overall 85% effectiveness of Covishield vaccine while in 53% the efficacy of developing antibodies was maximum. Dr. Nita Sahi further added that of all the people who were vaccinated, none had significant side effects during and after vaccination.
Commenting on the PMCH study, Dr. A. P. Gupta, Principal and Controller, PMCH told that this study has quite promising results but quite contradictory to the study reported by King George Medical University (K G M U), Lucknow where antibody was detected in merely 7% of vaccinated people and those who suffered from Corona, only 50% had detectable antibody.Chairman Rahul Agarwal stated that the present study has been sent for publication in an international journal. He further added that this study will be continued and antibody levels will be assessed after 6 months to know in how many people the capacity to fight against Corona persists.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
